Aprea Therapeutics (NASDAQ:APRE) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Aprea Therapeutics (NASDAQ:APRE) in a research note published on Tuesday morning, Benzinga reports. The firm currently has a $20.00 price objective on the stock. HC Wainwright also issued estimates for Aprea Therapeutics’ Q1 2024 earnings at ($0.80) EPS, Q2 2024 earnings at ($0.80) EPS, Q3 2024 earnings at ($0.79) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($1.39) EPS, FY2025 earnings at ($0.58) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.68) EPS and FY2028 earnings at ($0.69) EPS.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $6.69 on Tuesday. The firm has a market cap of $25.02 million, a P/E ratio of -1.68 and a beta of 1.05. Aprea Therapeutics has a 1-year low of $2.78 and a 1-year high of $8.85. The firm’s 50-day simple moving average is $6.39 and its 200-day simple moving average is $5.01.

Insider Buying and Selling

In other news, Director Bernd R. Seizinger acquired 6,860 shares of the stock in a transaction on Wednesday, March 13th. The stock was bought at an average price of $7.29 per share, with a total value of $50,009.40. Following the completion of the transaction, the director now directly owns 33,685 shares of the company’s stock, valued at $245,563.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last quarter, insiders acquired 9,870 shares of company stock valued at $71,952. 20.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Aprea Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in APRE. Vanguard Group Inc. lifted its stake in Aprea Therapeutics by 26.9% during the fourth quarter. Vanguard Group Inc. now owns 34,688 shares of the company’s stock worth $163,000 after purchasing an additional 7,347 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Aprea Therapeutics by 4.7% during the second quarter. Renaissance Technologies LLC now owns 311,754 shares of the company’s stock worth $234,000 after purchasing an additional 13,854 shares during the last quarter. Geode Capital Management LLC bought a new position in Aprea Therapeutics during the second quarter worth $74,000. Millennium Management LLC lifted its stake in Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock valued at $53,000 after buying an additional 43,293 shares during the last quarter. Finally, Royal Bank of Canada lifted its stake in Aprea Therapeutics by 13,788.0% in the fourth quarter. Royal Bank of Canada now owns 44,025 shares of the company’s stock valued at $207,000 after buying an additional 43,708 shares during the last quarter. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.